NO965207L - Sammensetning for indusering av mukosal immunrespons - Google Patents

Sammensetning for indusering av mukosal immunrespons

Info

Publication number
NO965207L
NO965207L NO965207A NO965207A NO965207L NO 965207 L NO965207 L NO 965207L NO 965207 A NO965207 A NO 965207A NO 965207 A NO965207 A NO 965207A NO 965207 L NO965207 L NO 965207L
Authority
NO
Norway
Prior art keywords
immune response
antigen
inducing
composition
site
Prior art date
Application number
NO965207A
Other languages
English (en)
Norwegian (no)
Other versions
NO965207D0 (no
Inventor
Bruno Guy
Jean Haensler
Marie-Jose Quentin-Millet
Original Assignee
Pasteur Merieux Serums Vacc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Merieux Serums Vacc filed Critical Pasteur Merieux Serums Vacc
Publication of NO965207D0 publication Critical patent/NO965207D0/no
Publication of NO965207L publication Critical patent/NO965207L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO965207A 1995-04-07 1996-12-05 Sammensetning for indusering av mukosal immunrespons NO965207L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9504433A FR2732605B1 (fr) 1995-04-07 1995-04-07 Composition destinee a l'induction d'une reponse immunitaire mucosale
PCT/FR1996/000534 WO1996031235A1 (fr) 1995-04-07 1996-04-09 Composition destinee a l'induction d'une reponse immunitaire mucosale

Publications (2)

Publication Number Publication Date
NO965207D0 NO965207D0 (no) 1996-12-05
NO965207L true NO965207L (no) 1996-12-05

Family

ID=9478070

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965207A NO965207L (no) 1995-04-07 1996-12-05 Sammensetning for indusering av mukosal immunrespons

Country Status (10)

Country Link
US (1) US6126938A (fr)
EP (1) EP0765170A1 (fr)
JP (1) JPH10501556A (fr)
AU (1) AU5504996A (fr)
CA (1) CA2192473A1 (fr)
FR (1) FR2732605B1 (fr)
HU (1) HUP9700037A3 (fr)
NO (1) NO965207L (fr)
NZ (1) NZ306483A (fr)
WO (1) WO1996031235A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
GB9626864D0 (en) * 1996-12-24 1997-02-12 Smithkline Beecham Biolog Vaccine
KR19990008155A (ko) * 1995-04-28 1999-01-25 랜스 고든 다가, 재조합 우레아제 백신
US20020165183A1 (en) * 1999-11-29 2002-11-07 Hans Herweijer Methods for genetic immunization
US6248551B1 (en) 1997-03-28 2001-06-19 Institut Pasteur Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides
FR2762787B1 (fr) * 1997-04-30 2000-10-06 Pasteur Merieux Serums Vacc Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1
EP0979100A1 (fr) * 1997-04-30 2000-02-16 Merieux OraVax SNC COMPOSITION VACCINALE ANTI-$i(HELICOBACTER) COMPRENANT UN ADJUVANT DE TYPE TH1
FR2762788B1 (fr) * 1997-04-30 2000-10-06 Pasteur Merieux Serums Vacc Composition vaccinale anti-helicobacter pour usage par voie systemique sous-diaphragmatique
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
EP1073745B1 (fr) * 1998-04-30 2004-12-01 Chiron S.r.l. Immunisation et traitement anti-infectieux
EP1105159A2 (fr) * 1998-06-19 2001-06-13 Mérieux Oravax Enterotoxine thermolabile et toxine cholerique dans des procedes d'immunisation parenterale contre les infections a helicobacter
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
US20040157277A1 (en) * 2002-03-08 2004-08-12 Clancy Robert Llewellyn Methods for predicting and/or diagnosing the risk of gastric cancer
AUPQ854100A0 (en) * 2000-07-03 2000-07-27 Helirad Pty Ltd Methods for monitoring treatment of helicobacter infection
CA2414846A1 (fr) * 2000-07-05 2002-01-24 Merieux Oravax Combinaisons immunologiques pour la prophylaxie et la therapie d'une infection par helicobacter pylori
FR2814958B1 (fr) * 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
US7264800B2 (en) * 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
US20040016013A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent
MXPA05000778A (es) * 2002-07-18 2005-08-29 Helix Biopharma Corp Uso de ureasa para inhibir el crecimiento de celulas cancerosas.
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US20040014704A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent induces tolerance
MXPA06001669A (es) 2003-08-12 2006-04-28 3M Innovative Properties Co Compuestos que contienen imidazo-oxima sustituidos.
NZ545412A (en) 2003-08-27 2008-12-24 Coley Pharm Group Inc Aryloxy and arylalkyleneoxy substituted imidazoquinolines
JP2007504269A (ja) 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Ｃｄ５＋ｂ細胞リンパ腫の治療方法
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
EP1673087B1 (fr) 2003-10-03 2015-05-13 3M Innovative Properties Company Imidazoquinolines a substitution alcoxy
WO2005048933A2 (fr) 2003-11-14 2005-06-02 3M Innovative Properties Company Composes d'un anneau d'imidazo substitues par oxime
CN1906192A (zh) 2003-11-14 2007-01-31 3M创新有限公司 羟胺取代的咪唑环化合物
AU2004293078B2 (en) 2003-11-25 2012-01-19 3M Innovative Properties Company Substituted imidazo ring systems and methods
US7198785B2 (en) * 2003-12-09 2007-04-03 Brown University Systems and methods related to degradation of uremic toxins
JP2007517035A (ja) 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
EP1699788A2 (fr) 2003-12-30 2006-09-13 3M Innovative Properties Company Sulfonamides d'imidazoquinolinyle, d'imidazopyridinyle et d'imidazonaphtyridinyle
US20050208032A1 (en) * 2004-01-16 2005-09-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
WO2006009826A1 (fr) 2004-06-18 2006-01-26 3M Innovative Properties Company Thiazoloquinolines et thiazolonaphtyridines substitues par aryloxy et arylalkyleneoxy
WO2006038923A2 (fr) 2004-06-18 2006-04-13 3M Innovative Properties Company Imidazonaphthyridines substituees par aryle
JP2008526757A (ja) * 2004-12-30 2008-07-24 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤製剤および方法
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
CA2592904C (fr) 2004-12-30 2015-04-07 3M Innovative Properties Company Composes chiraux a cycle [1,2]imidazo[4,5] fusionne
JP2008530022A (ja) 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫反応調節物質を含む水性ゲル処方物
EP1846405A2 (fr) 2005-02-11 2007-10-24 3M Innovative Properties Company Composes cycliques imidazo 4,5-c substitues par oxime et hydroxylamine et procedes associes
CA2602683A1 (fr) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines et analogues associes
CA2602590A1 (fr) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Composes cycliques 1-pyrazolo[3,4-c] substitues comme modulateurs de la biosynthese de cytokine destines au traitement d'infections virales et de maladies neoplastiques
WO2008008432A2 (fr) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Composés à cycle [1,2] imidazo [4,5-c] fusionné chiral substitué et procédés correspondants

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB2237510B (en) * 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
US5562909A (en) * 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
JP3919812B2 (ja) * 1993-07-27 2007-05-30 シーエスエル、リミテッド Ｈ．ピロリ関連胃十二指腸疾患の治療
AU2234995A (en) * 1994-04-29 1995-11-29 Pharmacia & Upjohn Company Feline immunodeficiency virus vaccine
US5897475A (en) * 1994-10-05 1999-04-27 Antex Biologics, Inc. Vaccines comprising enhanced antigenic helicobacter spp.
GB9503824D0 (en) 1995-02-25 1995-04-19 Allen Jones James Oil-slick containment

Also Published As

Publication number Publication date
HUP9700037A2 (hu) 1998-10-28
NO965207D0 (no) 1996-12-05
JPH10501556A (ja) 1998-02-10
CA2192473A1 (fr) 1996-10-10
US6126938A (en) 2000-10-03
HUP9700037A3 (en) 2002-04-29
FR2732605A1 (fr) 1996-10-11
WO1996031235A1 (fr) 1996-10-10
EP0765170A1 (fr) 1997-04-02
NZ306483A (en) 1998-08-26
AU5504996A (en) 1996-10-23
FR2732605B1 (fr) 1997-05-16
MX9606195A (es) 1998-06-28

Similar Documents

Publication Publication Date Title
Cancado Long term evaluation of etiological treatment of Chagas disease with benznidazole
HUP9700037A2 (hu) Nyálkahártya-immunválasz kiváltására szolgáló kompozíció
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
NO953182L (no) Farmasöytisk preparat for topisk administrering av antigener og/eller vaksiner til pattedyr via en slimhinnemembran
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
YU59092A (sh) Formulacije aerosola koji ne sadrže hlorofluorougljenična jedinjenja
NO20006194D0 (no) Farmasöytisk sammensetning for behandling av funksjonell dyspepsi og/eller irriterbar innvollssyndrom og ny anvendelse av substanser deri
DK0760649T3 (da) Præparater af fluticason-propionat
BR9306042A (pt) Método para tratar uma doença auto-immune em um mamifero e formas de dosagens farmacêuticas oral e inalável
NO20003775L (no) FremgangsmÕte for behandling av inflammatoriske sykdommer ved anvendelse av varmesjokkproteiner
EE200000536A (et) Ravimkoostised ja meetodid peroraalsete vaktsiinide ning terapeutiliste ainete süsteemse toime saamiseks
DK0794794T3 (da) Fremgangsmåde, sammensætninger og sæt til forögelse af oral biotilgængelighed for farmaceutiske midler
IT1245761B (it) Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
TR200001977T2 (tr) Lipofilik glukokortikosteroit içeren miseller ihtiva eden bileşimler
NO953874L (no) Farmasöytisk preparat inneholdende lipofile legemidler
PT918507E (pt) Formulacoes em aerossol
ES2031805T1 (es) Derivados del t-4 soluble.
KR950700758A (ko) 비-이온성 계면활성제 소포를 함유하는 백신(Vaccines containing non ionic surfactant vesicles)
NO975709L (no) Nye 19-nor-pregnan-steroider for indusering av hypototalamiske effekter
NO922936L (no) Fremstilling av fettsyremedikamenter
GR1001437B (el) Ζαχαροπλαστικό σύστημα χορηγήσεως φαρμακολογικώς δραστικών ουσιών.
FI973691A7 (fi) Amlodipiinia tai sen suolaa tai felodipiinia ja ACE:n estäjää sisältäv iä koostumuksia
FI913036A0 (fi) Terapeutiskt aktiv substituerad benzimidazol och foerfarande foer dess framstaellning.
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
FR2763592B1 (fr) Nouveaux derives glycosyles des ginkgolides, leur application en tant que medicaments et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application